<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04345796</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0127</org_study_id>
    <nct_id>NCT04345796</nct_id>
  </id_info>
  <brief_title>Pharmacological Reduction of Right Ventricular Enlargement</brief_title>
  <acronym>PROVE</acronym>
  <official_title>Multicenter, Randomized, 2 x 2 Factorial, Phase 3 Study to Assess the Efficacy of Carvedilol and Empagliflozin on Improvement of Right Ventricular Remodeling in Patients With Severe Functional Tricuspid Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chong Kun Dang Pharmaceutical Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Functional tricuspid regurgitation (TR) has been regarded as a secondary phenomenon of heart&#xD;
      failure (HF), mitral valve (MV) disease or atrial fibrillation. Regardless of left&#xD;
      ventricular (LV) function or pulmonary artery pressure, presence of moderate or greater&#xD;
      functional TR is associated with poor prognosis. When a patient develops functional TR, it&#xD;
      causes RV dilation and tricuspid annular enlargement, which also lead to deterioration of TR.&#xD;
      A vicious cycle of significant TR, RV volume overload, tricuspid annular dilation and&#xD;
      consequent aggravation of TR is accepted as a main determinant of the poor clinical outcome&#xD;
      of patients with TR. Therefore, therapies that induce reverse remodeling of the RV and&#xD;
      consequently reduce TR, may improve clinical outcomes. However, there have been no proven&#xD;
      medical therapies for TR. The investigators hypothesize that carvedilol or empagliflozin is&#xD;
      effective on improving RV remodeling in patients with functional severe TR and try to examine&#xD;
      this hypothesis in a multicenter, 2x2 factorial, and randomized comparison study using&#xD;
      cardiac MRI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Functional tricuspid regurgitation (TR) has been regarded as a secondary phenomenon of heart&#xD;
      failure (HF), mitral valve (MV) disease or atrial fibrillation. The prevalence of functional&#xD;
      TR was reported to be 25-64% in patients with either ischemic or non-ischemic cardiomyopathy.&#xD;
      Regardless of left ventricular (LV) function or pulmonary artery pressure, presence of&#xD;
      moderate or greater functional TR is associated with poor prognosis. When a patient develops&#xD;
      functional TR, it causes RV dilation and tricuspid annular enlargement, which also lead to&#xD;
      deterioration of TR. A vicious cycle of significant TR, RV volume overload, tricuspid annular&#xD;
      dilation and consequent aggravation of TR is accepted as a main determinant of the poor&#xD;
      clinical outcome of patients with TR. Because the quantitative assessment of RV size and&#xD;
      function using echocardiography is often limited due to the complex geometry of RV, cardiac&#xD;
      magnetic resonance imaging (MRI) has emerged as a gold standard for evaluating RV volume and&#xD;
      function with excellent accuracy and reproducibility. The investigators previously reported&#xD;
      that RV end-systolic volume index (ESVI) and RV end-diastolic volume index (EDVI) measured by&#xD;
      MRI were significantly larger in severe TR patients, and also found that preoperative RV ESVI&#xD;
      and RV ejection fraction (EF) on MRI were independent predictors of cardiac death and&#xD;
      postoperative adverse events in patients who underwent TV surgery for severe functional TR.&#xD;
      Therefore, therapies that induce reverse remodeling of the RV and consequently reduce TR, may&#xD;
      improve clinical outcomes. However, there have been no proven medical therapies for TR. The&#xD;
      morbidity and mortality of patients with functional TR remain high and novel therapeutic&#xD;
      agents are needed to improve the prognosis of patients with functional TR. The investigators&#xD;
      hypothesize that carvedilol or empagliflozin is effective on improving RV remodeling in&#xD;
      patients with functional severe TR and try to examine this hypothesis in a multicenter, 2x2&#xD;
      factorial, and randomized comparison study using cardiac MRI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>2 x 2 factorial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>To study efficacy of carvedilol, participants will be assigned to a carvedilol or to placebo and the identity of the treatment will be concealed by the use of study drugs that are identical in packaging, labeling, appearance and odor. Participants allocated to the SGLT2 inhibitor arm will receive empagliflozin 10mg.&#xD;
All imaging studies will be analyzed by core laboratory investigators who will be blinded to treatment assignment from the time of randomization until database lock.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of RV end-systolic volume index</measure>
    <time_frame>from baseline to 12 months follow-up</time_frame>
    <description>Change of RV end-systolic volume index by cardiac MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of RV end-diastolic volume index</measure>
    <time_frame>from baseline to 12 months follow-up</time_frame>
    <description>Change of RV end-diastolic volume index by cardiac MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of RV ejection fraction</measure>
    <time_frame>from baseline to 12 months follow-up</time_frame>
    <description>Change of RV ejection fraction by cardiac MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of vena contract width of TR</measure>
    <time_frame>from baseline to 12 months follow-up</time_frame>
    <description>Change of vena contract width of TR by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of death from cardiovascular causes or hospitalization for heart failure</measure>
    <time_frame>the entire follow-up period (continuing until 12 months after the last patient was enrolled)</time_frame>
    <description>Clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of death from any causes</measure>
    <time_frame>the entire follow-up period (continuing until 12 months after the last patient was enrolled)</time_frame>
    <description>Clinical outcome</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <condition>Right Ventricular Dilatation</condition>
  <arm_group>
    <arm_group_label>carvedilol+empagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive carvedilol SR 16mg and empagliflozin 10mg qd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>carvedilol alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive carvedilol SR 16mg alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive empagliflozin 10mg and matching placebo of carvedilol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive matching placebo of carvedilol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol+Empagliflozin</intervention_name>
    <description>Group A</description>
    <arm_group_label>carvedilol+empagliflozin</arm_group_label>
    <other_name>Dilatrend SR+Jardiance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>Group B</description>
    <arm_group_label>carvedilol alone</arm_group_label>
    <other_name>Dilatrend SR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Group C</description>
    <arm_group_label>empagliflozin alone</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Group D</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Matching placebo of Dilatrend SR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must agree to the study protocol and provide written informed consent&#xD;
&#xD;
          -  Outpatients ≥ 20 years of age, male or female&#xD;
&#xD;
          -  Patients with severe functional tricuspid regurgitation&#xD;
&#xD;
               -  TR whose vena contracta ≥0.7cm or central jet area &gt; 10 square cm and which&#xD;
                  lasted &gt; 6 months under medical treatment&#xD;
&#xD;
               -  LV ejection fraction ≥ 40%&#xD;
&#xD;
          -  Dyspnea of NYHA functional class II or III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity or allergy to the study drugs, drugs of similar chemical&#xD;
             classes, as well as known or suspected contraindications to the study drug&#xD;
&#xD;
          -  Current use or prior use of a SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor&#xD;
&#xD;
          -  Significant left-sided valve disease&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;40%&#xD;
&#xD;
          -  Marked bradycardia (&lt;50 beats/min) or 2nd or 3rd degree AVB, sinus node dysfunction&#xD;
&#xD;
          -  Severe pulmonary hypertension: TR Vmax &gt;4m/s at screening (including Cor pulmonale)&#xD;
&#xD;
          -  Medical history of hospitalization within 6 weeks&#xD;
&#xD;
          -  Current acute decompensated heart failure or dyspnea of NYHA functional class IV&#xD;
&#xD;
          -  Symptomatic hypotension and/or a SBP &lt; 90 mmHg at screening Estimated GFR &lt; 30&#xD;
             mL/min/1.73 square m&#xD;
&#xD;
          -  History of ketoacidosis, Type 1 diabetes&#xD;
&#xD;
          -  Evidence of hepatic disease as determined by any one of the following: AST or ALT&#xD;
             values exceeding 2 x upper limit of normal (ULN) at screening visit (Visit 0), history&#xD;
             of hepatic encephalopathy, history of esophageal varices, or history of portocaval&#xD;
             shunt.&#xD;
&#xD;
          -  Acute coronary syndrome, stroke, severe peripheral artery disease or major CV surgery&#xD;
             or PCI within 3 months&#xD;
&#xD;
          -  History of severe pulmonary disease (asthma, COPD with bronchial hypersensitivity)&#xD;
&#xD;
          -  Secondary hypertension such as pheochromocyotoma&#xD;
&#xD;
          -  Acute pulmonary thromboembolism&#xD;
&#xD;
          -  Variant angina, vocal cord edema, severe allergic rhinitis&#xD;
&#xD;
          -  Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant, unless they are using a barrier method plus a hormonal method&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  Contraindication for MRI&#xD;
&#xD;
               -  Presence of pacemaker or ICD, implanted metallic objects, claustrophobia&#xD;
&#xD;
               -  Severe beat-to-beat variation&#xD;
&#xD;
          -  Galactose intolerance, Lapp lactose deficiency, glucose-galactose malabsorption&#xD;
&#xD;
          -  Any clinically significant abnormality identified at the screening visit, physical&#xD;
             examination, laboratory tests, or electrocardiogram which, in the judgment of the&#xD;
             investigator, would preclude safe completion of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DUK HYUN KANG</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DUK HYUN KANG, MD</last_name>
    <phone>82-2-3010-3166</phone>
    <email>dhkang@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duk Hyun Kang, MD, PhD</last_name>
      <phone>82-2-3010-3166</phone>
      <email>dhkang@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>Seung-Ah Lee, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Duk Hyun Kang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seung Woo Park, MD, PhD</last_name>
      <email>parksmc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Seung Woo Park, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yong-Jin Kim, MD, PhD</last_name>
      <email>kimdamas@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Yong-Jin Kim, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 12, 2020</study_first_submitted>
  <study_first_submitted_qc>April 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Duk-Hyun Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

